• Publications
  • Influence
Pharmacokinetics of quinolones in renal insufficiency.
The pharmacokinetics of the new fluoroquinolone derivatives have been extensively studied in patients with various degrees of chronic renal insufficiency and for the drugs almost exclusively excreted, in unchanged form, via the renal route, Dosage adjustments are required, particularly in severe renal failure.
Pharmacokinetics of sparfloxacin in patients with renal impairment
A significant relationship between pharmacokinetic parameters and creatinine clearance was observed only for renal clearance of parent or conjugated sparfloxacin.
Disposition of Fleroxacin, a New Trifluoroquinolone, and Its Metabolites
Dangerous fleroxacin dosage may need to be reduced in patients with severe renal disease; in haemodialysed patients, treated every 2 days, a single dose of fler oxacin 400mg is recommended at the end of each dialysis session.
Relationship between renal function and disposition of oral cefixime
The findings suggest that the dose of cefixime needs to be reduced only in patients with severe renal failure, and that none of the metabolites, which may accumulte in uraemic patients, has antibacterial activity.
Fatal destructive cervical spondyloarthropathy.
Effect of the serotonin 5-HT4 receptor agonist cisapride on aldosterone secretion in corticotropic insufficiency and primary hyperaldosteronism.
Data show that cisapride stimulates aldosterone secretion in CI and PH patients, indicating that prolonged suppression of plasma ACTH or renin-ANG II activity does not affect the sensitivity of glomerulosa cells to 5-HT.
Pharmacokinetics and pharmacodynamics of zolpidem following repeated doses in hemodialyzed uraemic patients
Zolpidem may be administered safely to patients with severe renal impairment without any modification of the dosage regimen and was well tolerated as a hypnotic agent after the night‐time dosing.